酒精性和非酒精性脂肪性肝炎的监管科学与药物批准 - Suppr | 超能文献

文献检索
文档翻译
深度研究
学术资讯

Zotero 插件

邀请有礼
套餐&价格
历史记录

应用&插件

Zotero 插件浏览器插件 Mac 客户端 Windows 客户端微信小程序

定价

高级版会员购买积分包购买API积分包

服务

文献检索文档翻译深度研究 API 文档 MCP 服务

关于我们

关于 Suppr 公司介绍联系我们用户协议隐私条款

关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究

粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.酒精性和非酒精性脂肪性肝炎的监管科学与药物批准

Gastroenterology. 2016 Jun;150(8):1723-7. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.

2

Drug development of nonalcoholic fatty liver disease: challenges in research, regulatory pathways, and study endpoints.非酒精性脂肪性肝病的药物研发：研究中的挑战、监管途径及研究终点

Expert Opin Drug Discov. 2021 Feb;16(2):125-134. doi: 10.1080/17460441.2020.1811674. Epub 2020 Oct 22.

3

Transforming Drug Development in Heart Failure: Navigating the Regulatory Crossroads.心力衰竭药物研发的变革：穿越监管十字路口

Circ Heart Fail. 2016 Oct;9(10). doi: 10.1161/CIRCHEARTFAILURE.116.003192.

4

Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?非酒精性脂肪性肝炎研究能否有助于酒精性脂肪性肝炎的治疗管理？

Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008.

5

Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration.非酒精性脂肪性肝炎：美国食品药品监督管理局肝脏病学与营养科的当前观点

Hepatology. 2021 May;73(5):2023-2027. doi: 10.1002/hep.31687.

6

End Points Must Be Clinically Meaningful for Drug Development in Nonalcoholic Fatty Liver Disease.终点指标对于非酒精性脂肪性肝病的药物研发必须具有临床意义。

Gastroenterology. 2016 Jan;150(1):11-3. doi: 10.1053/j.gastro.2015.11.017. Epub 2015 Nov 18.

7

Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.非酒精性脂肪性肝炎研发项目之前的概念验证研究结构。

Clin Pharmacol Ther. 2017 Apr;101(4):444-446. doi: 10.1002/cpt.560. Epub 2016 Dec 29.

8

Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).同时性代谢性和酒精相关性脂肪性肝病（SMAFLD）以及同时性代谢性和酒精相关性脂肪性肝炎（SMASH）。

Ann Hepatol. 2021 Sep-Oct;24:100526. doi: 10.1016/j.aohep.2021.100526.

9

Nonalcoholic steatohepatitis (NASH) drugs market.非酒精性脂肪性肝炎（NASH）药物市场。

Nat Rev Drug Discov. 2016 Nov 3;15(11):745-746. doi: 10.1038/nrd.2016.188.

10

Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway.非酒精性脂肪性肝炎：可用治疗选择有限，但有前景的药物正在研发中，且在监管审批途径方面取得了近期进展。

Drugs. 2015 Aug;75(12):1373-92. doi: 10.1007/s40265-015-0437-3.

引用本文的文献

1

-Allylmercaptocysteine improves alcoholic liver disease partly through a direct modulation of insulin receptor signaling.烯丙基巯基半胱氨酸部分通过直接调节胰岛素受体信号传导来改善酒精性肝病。

Acta Pharm Sin B. 2021 Mar;11(3):668-679. doi: 10.1016/j.apsb.2020.11.006. Epub 2020 Nov 13.

2

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.山奈酚减轻非酒精性脂肪性肝炎小鼠的脂肪变性和肝纤维化。

Sci Rep. 2019 Nov 7;9(1):16210. doi: 10.1038/s41598-019-52736-y.

3

Pharmacologic Management of Nonalcoholic Steatohepatitis.

本文引用的文献

1

Gaps in Knowledge and Research Priorities for Alcoholic Hepatitis.酒精性肝炎的知识空白与研究重点

Gastroenterology. 2015 Jul;149(1):4-9. doi: 10.1053/j.gastro.2015.05.015. Epub 2015 May 23.

2

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.肝纤维化而非其他组织学特征与非酒精性脂肪性肝病患者的长期预后相关。

Gastroenterology. 2015 Aug;149(2):389-97.e10. doi: 10.1053/j.gastro.2015.04.043. Epub 2015 Apr 29.

3

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: findings and recommendations from an American Association for the Study of Liver Diseases-U.S. Food and Drug Administration Joint Workshop.

非酒精性脂肪性肝炎的药物治疗

Gastroenterol Hepatol (N Y). 2018 Oct;14(10):582-589.

4

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials.非酒精性脂肪性肝炎（NASH）的未来药物治疗：2期和3期试验综述

J Clin Transl Hepatol. 2018 Sep 28;6(3):264-275. doi: 10.14218/JCTH.2017.00056. Epub 2018 Jun 28.

5

Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.非酒精性脂肪性肝病（NAFLD）的药物干预：一项网状Meta分析尝试

Cochrane Database Syst Rev. 2017 Mar 30;3(3):CD011640. doi: 10.1002/14651858.CD011640.pub2.

6

Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.基于双光子显微镜的纤维化相关参数定量分析（q-FP）用于模拟脂肪性肝炎的疾病进展。

Hepatology. 2017 Jun;65(6):1891-1903. doi: 10.1002/hep.29090. Epub 2017 Apr 28.

7

Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.酒精性和非酒精性脂肪性肝病之间的共性与差异

Gastroenterology. 2016 Jun;150(8):1695-7. doi: 10.1053/j.gastro.2016.04.038. Epub 2016 May 4.

非酒精性脂肪性肝炎药物及生物标志物开发中的挑战与机遇：美国肝病研究协会-美国食品药品监督管理局联合研讨会的结果与建议

Hepatology. 2015 Apr;61(4):1392-405. doi: 10.1002/hep.27678. Epub 2015 Mar 19.

4

Alcoholic hepatitis.酒精性肝炎

Dan Med J. 2014 Oct;61(10):B4755.

5

Alcoholic hepatitis: Prognosis and treatment.酒精性肝炎：预后与治疗

Gastroenterol Hepatol. 2014 Apr;37(4):262-8. doi: 10.1016/j.gastrohep.2014.02.001. Epub 2014 Mar 20.

6

A histologic scoring system for prognosis of patients with alcoholic hepatitis.酒精性肝炎患者预后的组织学评分系统。

Gastroenterology. 2014 May;146(5):1231-9.e1-6. doi: 10.1053/j.gastro.2014.01.018. Epub 2014 Jan 15.

7

Alcoholic hepatitis: current challenges and future directions.酒精性肝炎：当前挑战与未来方向

Clin Gastroenterol Hepatol. 2014 Apr;12(4):555-64; quiz e31-2. doi: 10.1016/j.cgh.2013.06.013. Epub 2013 Jun 28.

8

Comparison of MELD, HVPG, and their changes to predict clinically relevant endpoints in cirrhosis.比较终末期肝病模型（MELD）、肝静脉压力梯度（HVPG）及其变化以预测肝硬化的临床相关终点。

Scand J Gastroenterol. 2012 Feb;47(2):204-11. doi: 10.3109/00365521.2011.645500.

9

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.美国非酒精性脂肪性肝炎患者进行肝移植的频率和结果。

Gastroenterology. 2011 Oct;141(4):1249-53. doi: 10.1053/j.gastro.2011.06.061. Epub 2011 Jul 2.

10

Population-based risk factors and resource utilization for HCC: US perspective.基于人群的 HCC 风险因素和资源利用：美国视角。

Curr Med Res Opin. 2010 Sep;26(9):2183-91. doi: 10.1185/03007995.2010.506375.

酒精性和非酒精性脂肪性肝炎的监管科学与药物批准 - Suppr | 超能文献

Regulatory Science and Drug Approval for Alcoholic and Nonalcoholic Steatohepatitis.

作者信息

Sanyal Arun J, Miller Veronica

机构信息

Department of Medicine, VCU School of Medicine, Richmond, Virginia.

University of California School of Public Health, Berkeley, California.

出版信息

Gastroenterology. 2016 Jun;150(8):1723-7. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.

DOI:10.1053/j.gastro.2016.02.044

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6802739/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5057/6802739/42221814cf74/nihms-763630-f0003.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5057/6802739/42221814cf74/nihms-763630-f0003.jpg

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5057/6802739/42221814cf74/nihms-763630-f0003.jpg